“1. Introduction
1.1 Scope and Coverage
1.2 Report Description
2 Executive Summary
2.1 Biomarker Diagnosis Vs. Conventional Diagnosis
2.2 Why Diagnostic Biomarkers are Used in Diagnosis and Drug Development?
3 Market Overview
3.1 Key Application of Diagnostic Biomarkers in Top Technologies
3.1.1 Omics Technology
3.1.1.1 Applications of Omics Technology
3.1.1.1.1 Lung Disease Identification
3.1.1.1.2 Quantifying Abnormalities
3.1.1.1.3 Genetic Trait Diagnosis
3.1.1.1.4 Analyzing Drug Efficiency
3.1.1.1.5 Functional Food Development
3.1.1.1.6 Pharmacogenomics
3.1.1.1.7 Drivers
3.1.1.1.8 Restraints
3.1.1.1.8.1 Lengthy Process
3.1.1.1.8.2 Ethical Problems
3.1.1.1.8.3 Sample Collection
3.1.1.1.8.4 Gene Expression
3.1.1.1.8.5 Inefficiency in Pre-Disease Identification
3.1.2 Imaging Technology
3.1.2.1 Application of Diagnostic Imaging Technology
3.1.2.2 Drivers
3.1.2.2.1 Faster Test Result
3.1.2.2.2 Improved Nursing Services
3.1.2.2.3 Noninvasive Technique
3.1.2.3 Restraints
3.1.2.3.1 Radiation Effect
3.1.2.3.2 Complex Process
3.1.2.3.3 Genetic Variation
3.1.2.4 Trends
3.1.3 Bioinformatics
3.1.3.1 Applications of Bioinformatics
3.1.3.2 Drivers
3.1.3.2.1 Open Source of Information
3.1.3.2.2 Relevant Information
3.1.3.2.3 Forecasting of Information
3.1.3.3 Restraints
3.1.3.3.1 Difficulty in Practical Application
3.1.3.3.2 Over-Fitting
3.1.3.3.3 Complex Operation Process
3.1.3.3.4 Security Issue
3.1.3.3.5 Costly Management
3.1.3.3.6 Virtual Storage
3.1.4 Personalized Medicines
3.1.4.1 Drivers
3.1.4.1.1 Unique Solution
3.1.4.1.2 Minimal Invasive
3.1.4.1.3 Reduction in Failure
3.1.4.1.4 Effective Prescription
3.1.4.2 Restraints
3.1.4.2.1 Need Specialized Setup for Treatment
3.1.4.2.2 Liability Issue
3.1.4.2.3 Ethical Question
3.1.5 Others (Nutritional Technology)
3.2 Importance of Non-Invasive Diagnostics
3.3 Key Advantages of Dm
3.4 Regulatory Scenario
3.5 Reimbursement Issues
3.6 Key Patents and Analysis
3.7 Top Ten Factors Impacting DBM Market
3.7.1 Non-Invasive Technique
3.7.2 Drug Discovery and Development
3.7.3 Cost Effective Tool for Diagnosis
3.7.4 Multi-Marker Application
3.7.5 Accuracy and Reliability
3.7.6 Ethical Issues
3.7.7 Gene Level Diagnosis
3.7.8 Complex Processes
3.7.9 Government Regulations
3.7.10 Reimbursement Issues
3.8 Top Investment Pockets
3.9 Market Intelligence
3.9.1 Top Three Winning Strategies
3.9.1.1 Product Launch
3.9.1.2 Collaboration and Agreement
3.9.1.3 Merger and Acquisition
3.10 Market Dynamics
3.10.1 Drivers
3.10.1.1 Cost Effective
3.10.1.2 Non-Invasive
3.10.1.3 Accuracy in Result
3.10.1.4 Assistant in Clinical Trials
3.10.1.5 Multi-Marker Application
3.10.1.6 Gene Level Diagnosis
3.10.2 Restrains
3.10.2.1 Government Regulation
3.10.2.2 Ethical Problems
3.10.2.3 Conformation in Result
3.10.2.4 Complex Process
3.10.3 Opportunity
3.10.3.1 Local Market
3.10.3.2 Personalized Medicine
3.10.3.3 Tissue Specific Treatment
4 Global Diagnostic Biomarker Market by Types
4.1 Biomarker of Exposure
4.2 Biomarkers of Disease
5 Global Diagnostic Biomarker Market by Applications
5.1 Risk Assessment
5.1.1 Applications
5.1.1.1 Oncology Treatment
5.1.1.2 Cardiovascular Treatment
5.1.2 Drivers
5.1.2.1 Forecasting of Abnormal Conditions
5.1.2.2 Cost Effective
5.1.3 Restraints
5.1.3.1 Government Regulations
5.1.3.2 Ethical Issues
5.2 Development of Molecular Diagnostic
5.2.1 Application
5.2.1.1 Prenatal Diagnostics
5.2.1.2 Human Clinical Molecular Diagnostic Testing
5.2.1.3 Veterinary Molecular Diagnostic Testing
5.2.1.4 Identity Testing
5.2.1.5 Histocompatibility Testing
5.2.2 Drivers
5.2.2.1 Uniformity in Test Result
5.2.2.2 Cost Effective
5.2.2.3 Fast Result
5.2.2.4 More Profitable
5.2.2.5 Automation
5.2.3 Restraints
5.2.3.1 Not Applicable for Twins Genomes
5.2.3.2 Government Regulations
5.2.3.3 Ethical Issues
5.3 Disease Diagnosis
5.3.1 Oncology
5.3.1.1 Drivers
5.3.1.2 Restraints
5.3.1.2.1 Complex Process
5.3.1.2.2 Conformation in Result
5.3.1.2.3 Used for Early Diagnosis Only
5.3.2 Cardiology
5.3.2.1 Application
5.3.2.2 Drivers
5.3.2.2.1 Cost Effective
5.3.2.2.2 Tissue Specific
5.3.2.2.3 Accurate Result
5.3.2.3 Restraints
5.3.2.3.1 Loss of Specificity
5.3.2.3.2 Low Specificity
5.3.2.3.3 Low Sensitivity
5.3.3 Neurology
5.3.3.1 Application
5.3.3.2 Drivers
5.3.3.2.1 Relevant Information
5.3.3.2.2 Efficient Diagnosis
5.3.3.2.3 Assistant in Clinical Trials
5.3.3.3 Restraints
5.3.3.3.1 Complex Process
5.3.3.3.2 Chromosomal Variation
5.3.3.3.3 Hurdles in Tracking
5.3.3.4 Alzheimer鈥檚
5.3.3.5 Multiple Sclerosis
5.3.3.6 Parkinson’s Disease
5.3.3.7 Others (Renal Diseases, Urinal Disease)
5.4 Drug Discovery and Development
5.4.1 Application
5.4.2 Drivers
5.4.2.1 Increased Efficiency
5.4.2.2 High Quality Support
5.4.2.3 Cost Effective
5.4.2.4 Collaboration for Novel Development
5.4.3 Restraints
5.4.3.1 Drug Metabolism
5.4.3.2 Stability of Biomarkers
5.4.3.3 Complex Process
5.5 Drug Formulation
5.5.1 Application
5.5.2 Drivers
5.5.3 Restraint
5.6 Forensic Application
5.7 Others (Dna Fingerprinting and Others)
5.7.1 Blood Alcohol Concentration Biomarker
5.7.2 Dna Fingerprinting
6 Global Diagnostic Biomarker Market by Services
6.1 Sample Preparation
6.1.1 Application
6.1.1.1 Biological Mass Spectrometry
6.1.2 Drivers
6.1.2.1 Cost Effective
6.1.2.2 Sample Rigidity
6.1.2.3 Efficient Forensic Studies
6.1.3 Restraints
6.1.3.1 Complex Structure
6.1.3.2 Lack of Effectiveness
6.1.3.3 Extensive Fractionation
6.1.3.4 Loss of Biological Compounds
6.2 Assay Development
6.2.1 Application
6.2.1.1 Clinical Trials
6.2.1.2 Drug Development and Validation
6.2.1.3 Others
6.2.2 Drivers
6.2.2.1 Accuracy
6.2.2.2 Cost Effective
6.2.2.3 Timely Result
6.2.3 Restraints
6.2.3.1 Complexity in Technique
6.2.3.2 Tissue Specific
6.3 Biomarker Validation and Testing
6.3.1 Drivers
6.3.1.1 Reduce Failure Rate
6.3.2 Restraints
6.3.2.1 Clinical Errors
6.3.2.2 Time Consuming
6.4 Other Services
7 Global Diagnostic Biomarker Market by Geography
7.1 North America
7.2 Europe
7.3 Asia-Pacific
7.4 Row (Rest of World)
8 Competitive Landscape
8.1 Product Launch
8.1.1 Recent Development
8.2 Collaboration and Partnership
8.2.1 Recent Development
8.3 Clearance and Approval
8.3.1 Recent Development
8.4 Mergers and Acquisition
8.4.1 Recent Development
9 Company Profile
9.1 Abbott Laboratories, Inc.
9.1.1 Company Overview
9.1.2 Company Snapshot
9.1.3 Business Performance
9.1.4 Strategic Moves and Developments
9.1.4.1 Principal Strategies
9.1.4.2 Secondary Strategies
9.1.5 Swot Analysis & Strategic Conclusions
9.2 Agilent Technologies Inc.
9.2.1 Company Overview
9.2.2 Company Snapshot
9.2.3 Business Performance
9.2.4 Strategic Moves and Developments
9.2.4.1 Primary Strategies
9.2.4.2 Secondary Strategies
9.2.5 Swot Analysis & Strategic Conclusions
9.3 Aushon Biosystem
9.3.1 Company Profile
9.3.2 Company Snapshot
9.3.3 Strategic Moves and Developments
9.3.3.1 Primary Strategies
9.3.3.2 Secondary Strategies
9.3.4 Swot Analysis & Strategic Conclusions
9.4 Bio-Rad Laboratories
9.4.1 Company Profile
9.4.2 Company Snapshot
9.4.3 Business Performance
9.4.4 Strategic Moves and Developments
9.4.4.1 Primary Strategies
9.4.4.2 Secondary Strategies
9.4.5 Swot Analysis & Strategic Conclusions
9.5 Eisai Co. Ltd.
9.5.1 Company Profile
9.5.2 Company Snapshot
9.5.3 Business Performance
9.5.4 Strategic Moves and Developments
9.5.4.1 Primary Strategies
9.5.4.2 Secondary Strategies
9.5.5 Swot Analysis & Strategic Conclusions
9.6 Epistem Ltd.
9.6.1 Company Profile
9.6.2 Company Snapshot
9.6.3 Business Performance
9.6.4 Strategic Moves and Developments
9.6.4.1 Primary Strategies
9.6.4.2 Secondary Strategies
9.6.5 Swot Analysis & Strategic Conclusions
9.7 Ge Healthcare
9.7.1 Company Profile
9.7.2 Company Snapshot
9.7.3 Business Performance
9.7.4 Strategic Moves and Developments
9.7.4.1 Principle Strategies
9.7.4.2 Secondary Strategies
9.7.5 Swot Analysis & Strategic Conclusions
9.8 Roche Diagnostics Limited
9.8.1 Company Profile
9.8.2 Company Snapshot
9.8.3 Business Performance
9.8.4 Strategic Moves and Developments
9.8.4.1 Principal Strategies
9.8.4.2 Secondary Strategies
9.8.5 Swot Analysis & Strategic Conclusions
9.9 Siemens AG
9.9.1 Company Profile
9.9.2 Company Snapshot
9.9.3 Business Performance
9.9.4 Strategic Moves and Developments
9.9.4.1 Primary Strategies
9.9.4.2 Secondary Strategies
9.9.5 Swot Analysis & Strategic Conclusions
9.10 Thermo Fisher Scientific Inc.
9.10.1 Company Profile
9.10.2 Company Snapshot
9.10.3 Business Performance
9.10.4 Strategic Moves and Developments
9.10.4.1 Primary Strategies
9.10.4.2 Secondary Strategies
9.10.5 Swot Analysis & Strategic Conclusions”
“Table 1 Global Diagnostic Biomarker Market by Revenue 2011-2020 ($Million)
Table 2 Global Diagnostic Biomarker Market by Application 2011-2020 ($Million)
Table 3 Global Diagnostic Biomarker Market for Technology 2011-2020 ($Million)
Table 4 Diagnostic Biomarker Application Market 2011-2020 ($Million)
Table 5 Diagnostic Biomarker Application Market 2011-2020 ($Million)
Table 6 Global Diagnostic Biomarker Market of Imaging Technology 2011-2020 ($Million)
Table 7 Global Diagnostic Biomarker Market of Bioinformatics 2011-2020 ($Million)
Table 8 Global Diagnostic Biomarker Market of Personalized Medicine 2011-2020 ($Million)
Table 9 Global Diagnostic Biomarker Market of Other Diseases 2011-2020 ($Million)
Table 10 Biomarkers Market by Types in 2011-2020 ($Million)
Table 11 Global Market for Biomarkers of Exposure in 2011-2020 ($Million)
Table 12 Global Market for Biomarkers of Exposure in 2011-2020 ($Million)
Table 13 Diagnostic Biomarker Application Market in 2011-2020 ($Million)
Table 14 Global Diagnostic Biomarker Market Application Market in 2011-2020 ($Million)
Table 15 Global Diagnostic Biomarker Market of Risk Assessment in 2011-2020 ($Million)
Table 16 Global Diagnostic Biomarker Market for Development of Molecular Diagnostic in 2011-2020 ($Million)
Table 17 Diagnostic Biomarker Market of Disease Diagnosis in 2011-2020 ($Million)
Table 18 Global Diagnostic Biomarker Market for Development of Molecular Diagnostic in 2011-2020 ($Million)
Table 19 Global Diagnostic Biomarker Market of Cardiology Diagnosis in 2011-2020 ($Million)
Table 20 Global Diagnostic Biomarker Market of Cardiology Diagnosis in 2011-2020 ($Million)
Table 21 Global Diagnostic Biomarker Market of Neurology Diagnosis in 2011-2020 ($Million)
Table 22 Diagnostic Biomarker Market for Neurology Disease Diagnosis in 2011-2020 ($Million)
Table 23 Global Diagnostic Biomarker Market of Other Disease Diagnosis in 2011-2020 ($Million)
Table 24 Global Diagnostic Biomarker Market of Other Disease Diagnosis in 2011-2020 ($Million)
Table 25 Global Diagnostic Biomarker Market of Drug Formulation in 2011-2020 ($Million)
Table 26 Global Diagnostic Biomarker Market of Forensic Application in 2011-2020 ($Million)
Table 27 Global Diagnostic Biomarker Market of Other Diseases in 2011-202 ($Million)
Table 28 Diagnostic Biomarker Market of Services in 2011-202($Million)
Table 29 Global Diagnostic Biomarker Market of Services in 2011-2020 ($Million)
Table 30 Global Diagnostic Biomarker Market of Sample Preparation in 2011-2020 ($Million)
Table 31 Global Diagnostic Biomarker Market of Assay Development in 2011-2020 ($Million)
Table 32 Global Diagnostic Biomarker Market of Biomarker Validation in 2011-2020 ($Million)
Table 33 Global Diagnostic Biomarker Market of Other Services in 2011-2020 ($Million)
Table 34 Global Diagnostic Biomarker Market in 2011-2020 ($Million)
Table 35 Types of Developments From 2013-2010
Table 36 Recent Development in Product Launch
Table 37 Product Launches From 2013-2010
Table 38 Collaboration and Partnership
Table 39 Partnership and Collaboration From 2013-2010
Table 40 Recent Development in Clearance and Approval
Table 41 Diagnostic Biomarker Approval and Clearance From 2013-2010
Table 42 Recent Development in Mergers and Acquisition
Table 43 Merger and Acquisition From 2013-2010
Table 44 Abbott Laboratories Business Snapshot
Table 45 Agilent Technologies Inc. Business Snapshot
Table 46 Aushon Biosystem Business Snapshot
Table 47 Bio-Rad Laboratories Business Snapshot
Table 48 Eisai Co. Ltd Business Snapshot
Table 49 Epistem Company Business Snapshot
Table 50 GE Healthcare Business Snapshot
Table 51 Roche Diagnostics Limited Business Snapshot
Table 52 Siemens Inc. Business Snapshot
Table 53 Thermo Fisher Scientific Inc. Business Snapshot”
“Figure 1 Patents Application Filled by General Electrical for Imaging Technology in India (2012)
Figure 2 Spider-Chart for Changes in Key Advantages From 2013-2020
Figure 3 Expected Growth of Biomarkers Application for Cancer Testing
Figure 4 Patent Analysis by Geography 2013
Figure 5 Top 10 Key Strategies Spider Chart 2012-2020
Figure 6 Expected Growth in CAGR From 2011-2020 for Diagnostic Biomarker Technology
Figure 7 Expected Growth in CAGR From 2011-2020 for Diagnostic Biomarkers in Application
Figure 8 Expected Growth in CAGR From 2011-2020 for Diagnostic Biomarkers in Services
Figure 9 Top 3 Wining Strategies From 2012-2020
Figure 10 Top 10 Countries in Cancer Population (Per 100,000 People) 2011
Figure 11 Cancer Statistics for Estimated New Cases and Deaths in U.S. for 2012
Figure 12 Leading Causes of Mortality in U.S. 2012
Figure 13 Cost on Alzheimer`S Disease to U.S. in 2013 (in Billion)
Figure 14 Estimated Deaths Vs. Estimated Cases in Different Types of Cancer in North America 2013
Figure 15 Developmental Strategies Adopted From 2013-2010
Figure 16 Diagnostic Biomarker Product Launch by Companies From 2013-2010
Figure 17 Partnership and Collaboration of Companies From 2013-2010
Figure 18 Clearance and Approval of Top 5 Companies From 2013-2010
Figure 19 Mergers and Acquisition From 2013-2010
Figure 20 Abbott Laboratories, Inc. Financial Revenues by Business Units (2012)
Figure 21 Abbott Laboratories, Inc. Financial Revenues by Geography (2012)
Figure 22 SWOT Analysis of Abbott Laboratories
Figure 23 Agilent Technologies Inc. Financial Revenues by Business Units (2012)
Figure 24 Agilent Technologies Inc. Financial Revenues by Geography (2012)
Figure 25 SWOT Analysis of Agilent Technologies
Figure 26 SWOT Analysis of Aushon Biosystem
Figure 27 Bio-Rad Laboratories Financial Revenues by Business Units (2012)
Figure 28 Bio-Rad Laboratories Financial Revenues by Geography (2012)
Figure 29 SWOT Analysis of Bio-Rad Laboratories
Figure 30 Eisai Co. Ltd Financial Revenues by Business Units (2012)
Figure 31 Eisai Co. Ltd Financial Revenues by Geography (2012)
Figure 32 SWOT Analysis of Eisai Co. Ltd
Figure 33 Epistem Financial Revenues by Business Units (2012)
Figure 34 Epistem Financial Revenues by Geography (2012)
Figure 35 SWOT Analysis of Epistem
Figure 36 GE Healthcare Financial Revenues by Business Units (2012)
Figure 37 GE Healthcare Financial Revenues by Geography (2012)
Figure 38 SWOT Analysis GE Healthcare
Figure 39 Roche Diagnostics Limited Financial Revenues by Business Units (2012)
Figure 40 Roche Diagnostics Limited Financial Revenues (Diagnostic Division) by Geography (2012)
Figure 41 SWOT Analysis of Roche Diagnostics Limited
Figure 42 Siemens Inc. Financial Revenues by Business Units (2012)
Figure 43 Siemens Inc. Financial Revenues by Geography (2012)
Figure 44 SWOT Analysis of Siemens
Figure 45 Thermo Fisher Scientific Inc. Financial Revenues by Business Units (2012)
Figure 46 Thermo Fisher Scientific Inc. Financial Revenues by Geographic Areas (2012)
Figure 47 SWOT Analysis of Thermo Fisher Scientific Inc”